Phase 3CompletedAge-related condition

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) (N30-003)

A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause

Sponsor
Noven Therapeutics (Industry)
Enrollment
614 enrolled
Conditions
Postmenopausal Symptoms
Interventions
Brisdelle (paroxetine mesylate); Placebo capsules
Ages
adults, older adults
Registry
NCT01361308

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to assess the safety \& efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause.

Primary outcomes

  • Mean Change in Frequency of Moderate to Severe VMS From Baseline at Week 4 and Week 12.
  • Mean Change From Baseline in Hot Flash Severity at Week 4 and Week 12

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Registered

  6. Started